Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia

Genetics and Molecular Research

Volumn 13, Issue 2, 2014, Pages 2377-2384

  Luo, P ^a,b   Li, L ^a   Wang, L X ^c   Zhu, H H ^c   Du, S ^c   Wu, S L ^c   Han, Y G ^c   Wang, G G ^c  

^a SHANDONG UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Atorvastatin; Carotid atherosclerosis; Ezetimibe; Hypercholesterolemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; DRUG COMBINATION; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RESPONSE; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVENING DOSAGE; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; PROTEIN BLOOD LEVEL; RASH; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BLOOD; CAROTID ARTERY DISEASES; COMPLICATION; DRUG COMBINATION; METABOLISM; PATHOLOGY;

AGED; AZETIDINES; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL, LDL; DRUG COMBINATIONS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; PYRROLES;

EID: 84897555287     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.April.3.10     Document Type: Article

References (21)

1. Ballantyne CM, Weiss R, Moccetti T, Vogt A, et al. (2007). Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am. J. Cardiol. 99: 673-680.
2. Benge CD, Markley B and McFarland MS (2012). Role of aggressive LDL reduction in patients with coronary heart disease. South Med. J. 105: 48-55.
3. Clearfield MB (2003). A novel therapeutic approach to dyslipidemia. J. Am. Osteopath. Assoc. 103: S16-S20.
4. Fleg JL, Mete M, Howard BV, Umans JG, et al. (2008). Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J. Am. Coll. Cardiol. 52: 2198-2205.
5. Gandhi MJ (2008). Does 'ENHANCE' diminish confidence in ezetimibe? J. Assoc. Physicians India 56: 665-666.
6. Grigore L, Raselli S, Garlaschelli K, Redaelli L, et al. (2013). Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. Eur. J. Clin. Pharmacol. 69: 341-346.
7. Hayek S, Canepa EF, Sattar A, Gamalski S, et al. (2013). Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am. J. Cardiol. 111: 532-539.
8. Irie Y, Katakami N, Kaneto H, Kasami R, et al. (2012). Maximum carotid intima-media thickness improves the prediction ability of coronary artery stenosis in type 2 diabetic patients without history of coronary artery disease. Atherosclerosis 221: 438-444.
9. Heart Protection Study Collaborative Group, Jonathan E, Derrick B, Emma L, et al. (2011). C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 377: 469-476.
10. Kablak-Ziembicka A, Przewlocki T, Sokolowski A, Tracz W, et al. (2011). Carotid intima-media thickness, hsCRP and TNF-α are independently associated with cardiovascular event risk in patients with atherosclerotic occlusive disease. Atherosclerosis 214: 185-190.
11. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, et al. (2008). Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358: 1431-1443.
12. Keo HH, Baumgartner I, Hirsch AT, Duval S, et al. (2011). Carotid plaque and intima-media thickness and the incidence of ischemic events in patients with atherosclerotic vascular disease. Vasc. Med. 16: 323-330.
13. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, et al. (2006). Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 114: 281-288.
14. Nochioka K, Tanaka S, Miura M, Zhulanqiqige dE, et al. (2012). Ezetimibe improves endothelial function and inhibits Rho-kinase activity associated with inhibition of cholesterol absorption in humans. Circ. J. 76: 2023-2030.
15. Okada K, Iwahashi N, Endo T, Himeno H, et al. (2012). Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease. Atherosclerosis 224: 454-456.
16. Robertson CM, Gerry F, Fowkes R and Price JF (2012). Carotid intima-media thickness and the prediction of vascular events. Vasc. Med. 17: 239-248.
17. Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, et al. (2008). The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr. Med. Res. Opin. 24: 685-694.
18. Scirica BM, Cannon CP, Sabatine MS, Jarolim P, et al. (2009). Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin. Chem. 55: 265-273.
19. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, et al. (2001). Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357: 577-581.
20. Stein E, Stender S, Mata P, Sager P, et al. (2004). Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am. Heart J. 148: 447-455.
21. Wierzbicki AS and Mikhailidis DP (2002). Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Int. J. Cardiol. 84: 53-57.